5248042026-07-245248042026-07-242026-07-245248042026-07-24in-capmkt:FinancialYear1Member5248042026-07-24in-capmkt:FinancialYear2Member5248042026-07-24in-capmkt:FinancialYear3Member5248042026-07-242026-07-24in-capmkt:FinancialYear1Member5248042026-07-242026-07-24in-capmkt:FinancialYear2Member5248042026-07-242026-07-24in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure524804AUROBINDO PHARMA LIMITEDAUROPHARMANOTLISTEDINE406A01037NewAcquisition (including agreement to acquire)false2026-07-2316:30:002026-07-24Apitoria Pharma Private LimitedMaterial SubsidiaryA1 Biochem Group (A1 Biochem Group comprises of (a) A1 Biochem Labs (India) Private Limited, India (b) the business of A1 Biochem Research (India) Private Limited, India and (c) A1 Biochem Labs LLC, USA.)1024400000423000000876000000falsefalsetruePharmaceuticals industryThe transaction aligns with the Company’s strategic objective of expanding its presence in the life cycle of Active Pharmaceutical Ingredients (API) business. Apitoria is currently engaged in large-scale, regulatory-compliant API manufacturing. Through this acquisition of front-end research and development capability, the Company will be able to create a dedicated Contract Research, Development and Manufacturing (CRDMO) platform. It will expand the portfolio of the Company facilitating full service, longer life cycle engagement with the customers. This transaction is complementary to the current API manufacturing business of Apitoria. Further, transaction will grant access to an existing CRO platform with 50+ client base and completed 800+ projects in USA and create an integrated CRDMO platform complementing the existing manufacturing business of Apitoria. The acquisition will be subject to completion of the conditions prescribed under the Definitive Agreements.YesTransaction is subject to customary approvals.false90 - 120 days.Cash1312400000The CRO Business of A1 Biochem Group will be acquired at an enterprise value of USD 17 Million on a debt free and cash free basis. The Company will invest USD 13.6 Million for its 80% ownership in the A1 Biochem Group, subject to adjustments as on the closing of transaction.131240000000.80.8A1 Biochem Group is engaged in CRO business providing custom synthesis, medicinal chemistry, route scouting, analytical development, and rapid process scale-up services. A1 Biochem Group’s turnover during last three years is as follows: 2023-24: INR 608.9 million 2024-25: INR 1,062.2 million 2025-26: INR 1,024.4 million A1 Biochem Labs (India) Private Limited is incorporated on November 11, 2021. A1 Biochem Research (India) private Limited is incorporated on July 18, 2022. A1 Biochem Labs LLC, USA is incorporated in September 2015 A1 Biochem Group comprises of two state-of-the-art laboratories located in Wilmington, North Carolina, USA, and Hyderabad, India. The Group has presence in USA and India. The Group has also been engaged in exporting its services to Netherlands, France and Japan among other countries.2025-202610244000002024-202510622000002023-2024608900000India and USA